Is tofacitinib/Shangjie a sustained-release tablet?

Tofacitinib/Shangjie（Tofacitinib) is an oral JAK inhibitor. The dosage form is designed with full consideration of the actual needs of different diseases and patient groups. Currently, tofacitinib is mainly available in three dosage forms: regular tablets, extended-release tablets and oral solution. This diverse selection of dosage forms reflects the continuous optimization of drug research and development in precise medication and compliance management.

Ordinary tablets are the earliest dosage forms used in clinical practice. They usually need to be taken twice a day. They can take effect quickly and are suitable for patients who require relatively flexible dosage adjustment. Sustained-release tablets are designed for the convenience of taking medication and the stability of drug concentration for some patients. Sustained-release tablets can achieve slow release of the drug in the digestive tract through a special preparation process, allowing patients to maintain stable blood drug concentrations by taking it only once a day. This feature has significant advantages in improving compliance and reducing fluctuations in efficacy caused by missed doses.

In addition to tablets, tofacitinib also provides oral solution dosage forms, mainly for dysphagia or pediatric patients, ensuring the accessibility of the drug among different groups and the flexibility of individualized treatment plans. In clinical practice, the specific choice of dosage form needs to be based on the type of disease, duration of disease, individual differences and financial affordability of the patient. Doctors usually give personalized advice based on the patient's actual situation.

Therefore, tofacitinib not only exists in tablet form, but also in extended-release tablet form. For patients who need to simplify dosing frequency and improve medication compliance, extended-release tablets are often a more suitable choice, while for patients who need precise dosage adjustment, regular tablets may be more suitable. In the future, as the formulation process and patient needs are further subdivided, the dosage form selection of tofacitinib may continue to expand.

Reference materials:https://www.xeljanz.com/